Dexcom to showcase its pioneering G6 CGM system at DPC2018 exhibition


Continuous glucose monitoring (CGM) is transforming self management and care for people with type 1 diabetes. Not only does CGM technology eliminate the need for painful fingerstick blood glucose testing*, but it can also improve HbA1c levels and exposure to hypoglycaemia compared with routine self monitoring of blood glucose.

DPC2018 Gold Sponsor and exhibitor, Dexcom, has been a worldwide leader in R&D of glucose sensing devices for over 20 years. Its latest CGM system, the Dexcom G6, which received a CE mark earlier this year, is set to revolutionise diabetes management.

“We believe our new Dexcom G6 system will set new standards, both in terms of patient benefits and cost efficiency for the NHS,” says Karen Baxter, Senior Director Country Lead UK, IRE & Belgium. “We are keen to work with healthcare professionals across the UK, to make CGM more widely available through the NHS for patients with type 1 diabetes.

“We very much look forward to meeting DPC’s visitors at our stand, where they can see the Dexcom G6 and talk to our team of experts about CGM technology, and we also invite them to attend Prof Nick Oliver’s conference session on CGM.”

Prof Oliver’s presentation on ‘The benefits of CGM for patients with T1D – review of the scientific evidence on clinical outcomes and opportunities for NHS funding’ will include information on NICE guidance on the use of CGM for children and adults with T1D, along with outcomes data following the implementation of NICE guidance in NW London.

Dexcom’s mission with the Dexcom G6 has been to make management of T1D less intrusive and also to remove fingersticks altogether. So the slim, discreet device has an auto-applicator that easily inserts a small sensor just below the skin, where it can be worn for 10 days. It also requires zero fingersticks* – an enormous step forward for people with T1D, who can use 80,000 fingersticks per person in their lifetime with normal self-monitoring.

The Dexcom G6 has numerous features to help users with their diabetes management, including: information on where their glucose is heading; alerts and alarms – for example to warn users ahead of a hypoglycaemic event; wireless glucose data transmission for display on smart devices; and the option to share data with up to five people.

In clinical trials, say Dexcom, the G6 has been proven to lower HbA1c levels, reduce the risk of hypoglycaemia, increase time spent in range, and improve quality of life and wellbeing.

See the Dexcom G6 on Stand B5 at DPC2018 and find out more about Prof Oliver’s CGM presentation, which takes place in the T1 Diabetes stream at 12.15 on 14 November, here.


* If the glucose alerts and readings from the G6 do not match patients’ symptoms or expectations, patients should use a blood glucose meter to make diabetes treatment decisions.

Posted in